| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| David S Janowsky, John M Davi. Diagnosis and treatment of depression in patients with mental retardation. Current psychiatry reports. vol 7. issue 6. 2006-02-14. PMID:16318819. |
furthermore, there is a growing body of evidence that antidepressant treatments, especially administration of selective serotonin reuptake inhibitors, are effective in treating depression in mentally retarded patients. |
2006-02-14 |
2023-08-12 |
Not clear |
| C-J Hong, T-J Chen, Y W-Y Yu, S-J Tsa. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. The pharmacogenomics journal. vol 6. issue 1. 2006-02-13. PMID:16302021. |
serotonin systems appear to play a key role in the pathogenesis of major depression and the therapeutic mechanisms of antidepressants. |
2006-02-13 |
2023-08-12 |
Not clear |
| Charles B Nemerof. Use of atypical antipsychotics in refractory depression and anxiety. The Journal of clinical psychiatry. vol 66 Suppl 8. 2006-02-10. PMID:16336032. |
ziprasidone and aripiprazole augmentation of various selective serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in open-label studies. |
2006-02-10 |
2023-08-12 |
Not clear |
| George I Papakostas, Timothy J Petersen, Gustavo Kinrys, Alana M Burns, John J Worthington, Jonathan E Alpert, Maurizio Fava, Andrew A Nierenber. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. The Journal of clinical psychiatry. vol 66. issue 10. 2006-02-09. PMID:16259548. |
aripiprazole, an atypical antipsychotic agent with partial dopaminergic and serotonin 1a receptor agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. |
2006-02-09 |
2023-08-12 |
Not clear |
| Young-Ja Jeong, Sung-Chan Hong, Myeong Soo Lee, Min-Cheol Park, Yong-Kyu Kim, Chae-Moon Su. Dance movement therapy improves emotional responses and modulates neurohormones in adolescents with mild depression. The International journal of neuroscience. vol 115. issue 12. 2006-02-07. PMID:16287635. |
in conclusion, dmt may be effective in beneficially modulating concentrations of serotonin and dopamine, and in improving psychological distress in adolescents with mild depression. |
2006-02-07 |
2023-08-12 |
Not clear |
| Ronald M Salomon, John S Kennedy, Benjamin W Johnson, Jennifer Urbano Blackford, Dennis E Schmidt, Joseph Kwentus, Harry E Gwirtsman, John F Gouda, Richard G Shiav. Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 11. 2006-01-24. PMID:15856079. |
unipolar and bipolar depressions show abnormal behavioral manifestations of ultradian (less than 24 h) rhythms, but abnormal rhythms of the central neurotransmitters thought to be important for depression pathophysiology (eg dopamine (da) and serotonin (5-ht)) have not been shown in this time frame. |
2006-01-24 |
2023-08-12 |
human |
| Ronald M Salomon, John S Kennedy, Benjamin W Johnson, Jennifer Urbano Blackford, Dennis E Schmidt, Joseph Kwentus, Harry E Gwirtsman, John F Gouda, Richard G Shiav. Treatment enhances ultradian rhythms of CSF monoamine metabolites in patients with major depressive episodes. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 11. 2006-01-24. PMID:15856079. |
since antidepressant treatments normalize disrupted rhythms in depression (eg rapid-eye-movement sleep and hormonal rhythms), we hypothesized that depression-related changes in ultradian oscillations of da and 5-ht might be revealed during antidepressant treatment. |
2006-01-24 |
2023-08-12 |
human |
| Gerard J Marek, Raul Martin-Ruiz, Allyson Abo, Francesc Artiga. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 12. 2006-01-24. PMID:15886717. |
the addition of low doses of atypical antipsychotic drugs, which saturate 5-ht(2a) receptors, enhances the therapeutic effect of selective serotonin (5-hydroxytryptamine; 5-ht) reuptake inhibitors (ssris) in patients with major depression as well as treatment-refractory obsessive-compulsive disorder. |
2006-01-24 |
2023-08-12 |
Not clear |
| Per Svenningsson, Karima Chergui, Ilan Rachleff, Marc Flajolet, Xiaoqun Zhang, Malika El Yacoubi, Jean-Marie Vaugeois, George G Nomikos, Paul Greengar. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (New York, N.Y.). vol 311. issue 5757. 2006-01-24. PMID:16400147. |
the pathophysiology of depression remains enigmatic, although abnormalities in serotonin signaling have been implicated. |
2006-01-24 |
2023-08-12 |
mouse |
| Lawrence Scahil. Selective serotonin reuptake inhibitors in children and adolescents with major depression. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 27. issue 2. 2006-01-17. PMID:15962129. |
selective serotonin reuptake inhibitors in children and adolescents with major depression. |
2006-01-17 |
2023-08-12 |
Not clear |
| Ellen A Walker, Stephen J Kohut, Richard W Hass, Edward K Brown, Anupama Prabandham, Timothy Lefeve. Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology. vol 49. issue 8. 2006-01-17. PMID:16165167. |
serotonin(2c) (5-ht(2c)) receptors have been implicated to treat mood disorders such as depression and anxiety. |
2006-01-17 |
2023-08-12 |
mouse |
| L L Cornelissen, D P Brooks, A Wibberle. Female, but not male, serotonin reuptake transporter (5-HTT) knockout mice exhibit bladder instability. Autonomic neuroscience : basic & clinical. vol 122. issue 1-2. 2006-01-11. PMID:16023897. |
abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. |
2006-01-11 |
2023-08-12 |
mouse |
| A Rex, J P Voigt, H Fin. Anxiety but not arousal increases 5-hydroxytryptamine release in the rat ventral hippocampus in vivo. The European journal of neuroscience. vol 22. issue 5. 2006-01-10. PMID:16176361. |
central serotonin [5-hydroxytryptamine (5-ht)] is involved in the aetiology of numerous disease states, including depression and anxiety disorders. |
2006-01-10 |
2023-08-12 |
rat |
| Eric J Lenze, Michael C Munin, Robert E Ferrell, Bruce G Pollock, Elizabeth Skidmore, Francis Lotrich, Joan C Rogers, Tanya Quear, Patricia Houck, Charles F Reynold. Association of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype with depression in elderly persons after hip fracture. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 13. issue 5. 2006-01-06. PMID:15879594. |
association of the serotonin transporter gene-linked polymorphic region (5-httlpr) genotype with depression in elderly persons after hip fracture. |
2006-01-06 |
2023-08-12 |
Not clear |
| Graham J Emslie, Taryn L Mayes, Maryse Ruber. Continuation and maintenance therapy of early-onset major depressive disorder. Paediatric drugs. vol 7. issue 4. 2006-01-06. PMID:16117558. |
according to research of acute treatment of child and adolescent depression with pharmacotherapy, selective serotonin reuptake inhibitors (ssris) are considered the first-line treatment. |
2006-01-06 |
2023-08-12 |
Not clear |
| A Birkhofer, G Schmidt, H Först. [Relationships between mental and cardiac diseases]. MMW Fortschritte der Medizin. vol 147. issue 42. 2006-01-06. PMID:16281782. |
patients with a cardiac disease who suffer from episodes of depression should be treated with selective serotonin reuptake inhibitors. |
2006-01-06 |
2023-08-12 |
Not clear |
| Ayse Devrim Basterzi, Cigdem Aydemir, Cebrail Kisa, Sabahat Aksaray, Verda Tuzer, Kemal Yazici, Erol Gök. IL-6 levels decrease with SSRI treatment in patients with major depression. Human psychopharmacology. vol 20. issue 7. 2006-01-05. PMID:16158446. |
the objective of this study was to examine the serum levels of il-6 in patients with major depression and the changes occurring in il-6 levels during treatment with selective serotonin reuptake inhibitors (ssri). |
2006-01-05 |
2023-08-12 |
Not clear |
| A Bickel, J Kornhuber, C Maihöfner, A Ropoh. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline. A case report. Pharmacopsychiatry. vol 38. issue 6. 2006-01-05. PMID:16342007. |
we report on a patient, who was treated during an episode of depression with the selective serotonin reuptake inhibitor (ssri) sertraline and developed frequent migraine attacks under this therapeutical regime. |
2006-01-05 |
2023-08-12 |
Not clear |
| Keri A Lattimore, Steven M Donn, Niko Kaciroti, Alex R Kemper, Charles R Neal, Delia M Vazque. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of perinatology : official journal of the California Perinatal Association. vol 25. issue 9. 2006-01-03. PMID:16015372. |
selective serotonin reuptake inhibitors (ssris) are frequently used to treat depression during pregnancy and the postpartum period. |
2006-01-03 |
2023-08-12 |
Not clear |
| Patrizia Blardi, Arianna de Lalla, Renato Urso, Alberto Auteri, Alice Dell'Erba, Letizia Bossini, Paolo Castrogiovann. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. Journal of clinical psychopharmacology. vol 25. issue 3. 2005-12-30. PMID:15876907. |
citalopram is a selective serotonin reuptake inhibitor used in the treatment of depression. |
2005-12-30 |
2023-08-12 |
rat |